.... ok, so lately we've brought in some puzzle pieces for Greg Lemke <> Xetrios <> Salks Institute and a PS Targeting Patent and all other associated patents of Lemkes's and Salks all sold to "Kolltan"
so the puzzle gets bigger but at least we have a tie from Hakan Mellstedt to Gerald McMahon CEO of Kolltan...and PAV lists of some have shown Standish Fleming as well
enough for today..
-------------------------------------
Gordon Rustin M.D., MSc, FRCP Return to Angstrom Pharmaceuticals, Inc. Member of Clinical Trial Advisory Board
David J. Chaplin OXiGENE, Inc. Board Affiliations OXiGENE, Inc.
Tamar D. Howson S*BIO Pte Ltd. Board Affiliations OXiGENE, Inc.
Adrian Lewellyn Harris Collgard Biopharmaceuticals Ltd. Board Affiliations OXiGENE, Inc. Angstrom Pharmaceuticals, Inc.
Frederick W. Driscoll Flexion Therapeutics, Inc. Board Affiliations OXiGENE, Inc.
Gerald McMahon Kolltan Pharmaceuticals, Inc. Board Affiliations OXiGENE, Inc.
Robert S. Kerbel MetronomX, Pte. Ltd. Board Affiliations OXiGENE, Inc.
William D. Schwieterman Avidia, Inc. Board Affiliations OXiGENE, Inc.
Stanley Kaye Biotica Technology Limited Board Affiliations OXiGENE, Inc.
Dietmar W. Siemann OXiGENE, Inc. Board Affiliations OXiGENE, Inc.
Jan B. Vermorken Vaccinogen, Inc. Board Affiliations OXiGENE, Inc.
Lee S. Rosen OXiGENE, Inc. Board Affiliations OXiGENE, Inc.
Hakan Mellstedt Korea Stem Cell Bank Co., Ltd Board Affiliations OXiGENE, Inc.
Jeffrey S. Heier Ophthalmic Consultants of Boston, Inc. Board Affiliations OXiGENE, Inc.
Hilary Calvert Astex Therapeutics Limited Board Affiliations OXiGENE, Inc.
Standish M. Fleming Forward Ventures Board Affiliations Nereus Pharmaceuticals, Inc.
Jason S. Fisherman Synthesis Capital Board Affiliations Nereus Pharmaceuticals, Inc.
Erich Platzer HBM Partners Ltd. Board Affiliations Nereus Pharmaceuticals, Inc.
Frank V. AtLee Agenus Inc. Board Affiliations Nereus Pharmaceuticals, Inc.
Jim Van Heusden Karolinska Development AB (publ) Board Affiliations Nereus Pharmaceuticals, Inc.
Martin Rosenberg VantagePoint Capital Partners Board Affiliations Nereus Pharmaceuticals, Inc.
Gary Shearman Neuro-Hitech, Inc. Board Affiliations Nereus Pharmaceuticals, Inc.
Kenneth C. Anderson OncoPep, Inc. Board Affiliations Nereus Pharmaceuticals, Inc.
Lee Ellis Cerulean Pharma Inc. Board Affiliations Nereus Pharmaceuticals, Inc.
Kobi M. Sethna Nereus Pharmaceuticals, Inc. Board Affiliations Nereus Pharmaceuticals, Inc.
John C. Byrd Nereus Pharmaceuticals, Inc. Board Affiliations Nereus Pharmaceuticals, Inc.
Peter O'Dwyer TetraLogic Pharmaceuticals Corporation Board Affiliations Nereus Pharmaceuticals, Inc.
Martin Nash Genetronics Inc. Board Affiliations Angstrom Pharmaceuticals, Inc.
David C. U'Prichard Druid Consulting, LLC Board Affiliations Angstrom Pharmaceuticals, Inc.
Donald W. Grimm Aegis Therapeutics, LLC Board Affiliations Angstrom Pharmaceuticals, Inc.
Virgil D. Thompson Spinnaker Biosciences, Inc. Board Affiliations Angstrom Pharmaceuticals, Inc.
James A. Taylor Innate Immunotherapeutics Limited Board Affiliations Angstrom Pharmaceuticals, Inc.
Stephen B. Howell Aptose Biosciences Inc. Board Affiliations Angstrom Pharmaceuticals, Inc.
Malcolm J. P. Finlayson Angstrom Pharmaceuticals, Inc. Board Affiliations Angstrom Pharmaceuticals, Inc.
Kerry Dance Hamilton BioVentures Board Affiliations Angstrom Pharmaceuticals, Inc.
William R. Freeman Spinnaker Biosciences, Inc. Board Affiliations Angstrom Pharmaceuticals, Inc.
Bruce Dezube Collgard Biopharmaceuticals Ltd. Board Affiliations Angstrom Pharmaceuticals, Inc.
Michael H. Silverman Can-Fite BioPharma Ltd. Board Affiliations Angstrom Pharmaceuticals, Inc.
Nils Brünner WntResearch AB Board Affiliations Angstrom Pharmaceuticals, Inc.
Jennifer Lorenzen Angstrom Pharmaceuticals, Inc. Board Affiliations Angstrom Pharmaceuticals, Inc.
Frederick E. Reno Innate Immunotherapeutics Limited Board Affiliations Angstrom Pharmaceuticals, Inc.
Chi Yap Angstrom Pharmaceuticals, Inc. Board Affiliations Angstrom Pharmaceuticals, Inc.
Arup Das Angstrom Pharmaceuticals, Inc. Board Affiliations Angstrom Pharmaceuticals, Inc.
Interesting video below re: Rolf Stahel as he states:
"Everybody develops cancer all the time and the immune system gets rid of it. However, the tumors have developed mechanisms that they can fight off the immune system and they can find ways by secreting factors which block the immune cells or by having on the surface, receptors, which when the immune cells hit those receptors, they go inactive. Now, Immuno-Oncology is the idea to enable the immune system to fight back the cancer.."
"Immuno-Oncology for most of the part is clinical trials, but there have been agents - immune checkpoint inhibitors that have regulatory approval for clinical use. The thing is though, the results are...good, but there is so much more hope for better results that I would think that most of the physicians or centers that deal with Immuno-Oncology would like to treat the patient in trials to give him an even better chance than what is already available"
"I would think that most of the physicians or centers that deal with Immuno-Oncology would like to treat the patient in trials to give him an even better chance that what is already available"
...and that is coming from the President of the ESMO and sure sounds like this paradigm shift in medical treatment is happening so fast, that if the docs are aware of what is looming out there in PS Targeting land, that trials are where you will find your best chance for an even better chance than what is already available.